etoposide IV / Generic mfg. - LARVOL DELTA

Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial. (PubMed, Lancet) - P3 | "BrECADD guided by PET after two cycles is better tolerated and more effective than eBEACOPP in first-line treatment of adult patients with advanced-stage, classical Hodgkin lymphoma."

Journal • Metastases • P3 data • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

High-dose versus standard dose twice-daily thoracic radiotherapy in limited stage small-cell lung cancer: final survival data, long-term toxicity and relapse patterns in a randomised, open-label, phase II trial. (PubMed, J Thorac Oncol) - "Twice-daily TRT of 60 Gy/40 fractions was well tolerated and prolonged survival compared with 45 Gy/30 fractions in LS SCLC patients."

Journal • P2 data • Gastrointestinal Disorder • Lung Cancer • Oncology • Otorhinolaryngology • Pneumonia • Small Cell Lung Cancer • Solid Tumor

Final results of a multicentre pilot study evaluating brentuximab vedotin with cyclophosphamide, doxorubicin, etoposide and prednisone (BV-CHEP) for the treatment of aggressive adult T-cell leukaemia/lymphoma. (PubMed, Br J Haematol) - No abstract available

Journal • Adult T-Cell Leukemia-Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma

EA5181: Phase 3 Trial of Concurrent and Consolidative Durvalumab vs Consolidation Durva Alone for Unresectable Stage 3 NSCLC (IASLC-WCLC 2025) - "Methods : 662 pts with previously untreated, unresectable stage III A-C (N = 635) NSCLC or with mediastinal node recurrence after prior surgery (N = 27) and ECOG performance status (ECOG PS) 0-1 were randomized to either concurrent durvalumab with chemotherapy (weekly carboplatin/paclitaxel, cisplatin/pemetrexed x 2 cycles or cisplatin/etoposide x 2 cycles) and 60Gy radiotherapy (Arm A), or to CRT alone (Arm B). Concurrent and consolidation durvalumab with CRT in unresectable Stage III NSCLC did not improve OS compared to consolidation durvalumab alone. There were also no differences in ORR, PFS, failure patterns nor toxicity between arms."

P3 data • Lung Cancer • Non Small Cell Lung Cancer • Pneumonia • Solid Tumor

Randomized phase II clinical trial of cisplatin/carboplatin and etoposide (PE) alone or in combination with nivolumab as frontline therapy for extensive-stage small cell lung cancer (ES-SCLC): ECOG-ACRIN EA5161. (PubMed, Cancer) - "The combination of PE and nivolumab improves both PFS and OS for patients with ES-SCLC. No new safety signals were observed."

Clinical • Journal • P2 data • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Hypofractionated vs Conventional Fractionated Radiotherapy With Concurrent Chemotherapy for LS-SCLC: A Multi-Center Phase III Trial (IASLC-WCLC 2025) - "All patients received 4-6 cycles of cisplatin/carboplatin-etoposide chemotherapy (CT) every 3 weeks. These findings support the clinical adoption of HypoRT. Further investigation of HypoRT in combination with immunotherapy is warranted given its potential immune-sparing benefits."

Clinical • P3 data • Inflammation • Lung Cancer • Pneumonia • Small Cell Lung Cancer • Solid Tumor

Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study. (PubMed, Lancet Oncol) - P1, P3 | "Tarlatamab plus a PD-L1 inhibitor as maintenance after first-line chemo-immunotherapy showed a manageable safety profile with promising anticancer activity, supporting the ongoing phase 3 trial (NCT06211036)."

Journal • P1 data • Hematological Disorders • Infectious Disease • Lung Cancer • Neutropenia • Oncology • Pneumonia • Respiratory Diseases • Small Cell Lung Cancer • Solid Tumor • DLL3

Patterns of disease progression (PD) and efficacy associated with tumour burden from the phase III IMforte study of lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in ES-SCLC (ESMO 2025) - P3 | "Methods Eligible pts with ES-SCLC without PD after 1L induction tx with atezo, carboplatin, and etoposide were randomised 1:1 to maintenance tx q3w with lurbi 3.2 mg/m 2 + atezo 1200 mg or atezo until PD or unacceptable toxicity. Table: 2762MO Association of OS and IRF-PFS with maintenance BL tumour burden OS IRF-PFS Lurbi + atezo Atezo Lurbi + atezo Atezo Non-measurable disease only, n 67 59 67 59 Median, mo 16.4 12.2 7.3 2.8 Unstratified HR (95% CI) 0.75 (0.44, 1.28) 0.56 (0.36, 0.86) Measurable disease with baseline SOD <median, n 89 86 89 86 Median, mo 13.2 13.6 5.5 2.4 Unstratified HR (95% CI) 0.96 (0.62, 1.47) 0.58 (0.41, 0.82) Measurable disease with baseline SOD ≥median, n 86 96 86 96 Median, mo 11.7 8.6 4.2 1.6 Unstratified HR (95% CI) 0.59 (0.40, 0.86) 0.52 (0.37, 0.72) Conclusions Proportionately fewer IRF-defined PD events were observed in target/non-target lesions in the lurbi + atezo vs atezo arms. The addition of lurbi led to greater OS improvement..."

Clinical • P3 data • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Effects of antibiotic prophylaxis in first-line therapy of advanced stage classic Hodgkin lymphoma: An analysis of the GHSG HD21 study (ASH 2025) - "In the GHSG HD21 trial for advanced-stage classic Hodgkin lymphoma (AS-cHL), patients received polychemotherapy regimens (eBEACOPP[bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone] orBrECADD [brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, anddexamethasone]) with a risk to develop febrile neutropenia (FN) and/or infections. This comprehensive analysis of the HD21 trial demonstrates the efficacy of ABP and peg G-CSF in thetreatment of AS-cHL in preventing FN and higher-grade infections. This effect is most pronounced in thefirst cycle and in patients receiving BrECADD. Based on these results, we recommend the use of ABPduring the first cycle of the BrECADD regimen, at least."

Clinical • Metastases • Classical Hodgkin Lymphoma • Febrile Neutropenia • Hematological Malignancies • Hodgkin Lymphoma • Infectious Disease • Lymphoma • Neutropenia

Safety and Survival Update of Tarlatamab with Anti-PD-L1 as 1L Maintenance After Chemo-IO for ES-SCLC: DeLLphi-303 Ph1b Trial (IASLC-WCLC 2025) - P1, P3 | "Methods : Patients with ES-SCLC were eligible if they had completed 4 to 6 cycles of 1L platinum-etoposide chemotherapy and anti-PD-L1 (unless unavailable) without disease progression. Within 8 weeks from the start of the last chemo-immunotherapy cycle, patients received tarlatamab (10 mg IV Q2W) with either atezolizumab (1680 mg IV Q4W) or durvalumab (1500 mg IV Q4W) as 1L maintenance until disease progression...The median OS was 25.3 months (95% CI, 20.3-not reached) and the median PFS was 5.6 months (95% CI, 3.5-9.0) (Figure). Conclusions Tarlatamab in combination with anti-PD-L1 demonstrated an acceptable safety profile, with long-term tolerability and unprecedented OS."

Clinical • Lung Cancer • Small Cell Lung Cancer • Solid Tumor • DLL3

Tarlatamab with first-line chemoimmunotherapy for extensive stage small cell lung cancer (ES-SCLC): DeLLphi-303 study (ESMO 2025) - P1 | "c Fatal TRAE of septic shock related to platinum-etoposide chemotherapy. Conclusions The combination of tarlatamab with chemo-IO for 1L treatment of ES-SCLC demonstrated manageable safety with encouraging initial survival outcomes, supporting further investigation of this combination in the phase III DeLLphi-312 study."

Clinical • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN HODGKIN LYMPHOMA: A 16-YEAR SINGLE-CENTER EXPERIENCE FROM EHU 1ST NOVEMBER OF ORAN, ALGERIA (EBMT 2026) - "ASCT was administered as first-line consolidation therapy in 53 patients with advanced-stage disease (stage III–IV) and in 102 patients with relapsed or refractory R/R HL.CD34⁺ hematopoietic stem cells were mobilized using granulocyte colony-stimulating factor (G-CSF) alone (filgrastim or lenograstim) at a dose of 15 µg/kg/day for 5 days, or in combination with plerixafor in cases of mobilization failure...The EAM regimen included a total dose of etoposide 800 mg/m², cytarabine 8 g/m², and melphalan 140 mg/m²... ASCT is a safe and effective treatment for patients with Hodgkin lymphoma. Using predominantly fresh grafts, the procedure showed low treatment-related mortality, rapid hematologic recovery, high remission rates, and durable long-term outcomes."

Clinical • Bone Marrow Transplantation • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Transplantation • CD34

Real-World Safety and Outcomes of Tarlatamab in Extensive-Stage Small Cell Lung Cancer (IASLC-TTLC 2026) - "Primary endpoints included the 15-day incidence of cytokine release syndrome (CRS), immune effector cell–associated neurotoxicity syndrome (ICANS), tocilizumab use, and mortality...Nearly all patients received prior etoposide (99%), and many had prior immunotherapy exposure (atezolizumab 59%; durvalumab 24%); 26% received lurbinectedin...At 6 months, 117 patients had died (34.8%), and only 27 patients (8%) received subsequent systemic therapy, most commonly platinum agents, irinotecan, or topotecan... Tarlatamab demonstrated a safety profile and clinical outcomes comparable to those reported in the DeLLphi-304 trial. The limited use of subsequent therapies after progression underscores the critical need for improved post-tarlatamab treatment options in extensive-stage SCLC."

Clinical • Real-world • Real-world evidence • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia (clinicaltrials.gov) - P2 | N=30 | Recruiting | Sponsor: University of Washington | Not yet recruiting ➔ Recruiting

Enrollment open • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Oncology • T Acute Lymphoblastic Leukemia

Management of Pulmonary Large-Cell Neuroendocrine Carcinoma (LCNEC): An Updated Review. (PubMed, Clin Lung Cancer) - "For unresectable, locally advanced disease, concurrent chemoradiation with etoposide-cisplatin followed by consolidation durvalumab is recommended, although the optimal dose-fractionation and the duration of consolidation immunotherapy remain to be investigated. Among the most promising emerging treatment strategies are DLL3-targeting therapies, buoyed by the recent success of tarlatamab in SCLC. The evolving role of molecular profiling in prognostication and treatment decision-making is also examined."

Journal • Review • Endocrine Cancer • Lung Cancer • Neuroendocrine Carcinoma • Non Small Cell Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • DLL3

SCLC Outcomes and Real-World Insight with Tarlatamab, a Multi-Center Experience (IASLC-TTLC 2026) - "After tarlatamab, 9 patients received lurbinectedin, 2 topotecan, 2 irinotecan and 1 cisplatin/etoposide. Conclusion Tarlatamab was overall well-tolerated in this real-world cohort and demonstrated preliminary efficacy for active CNS metastases. Real world efficacy appears similar to clinical trial results."

Clinical • Real-world • Real-world evidence • Lung Cancer • Small Cell Lung Cancer • Solid Tumor

Dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-EPOCH) yields durable remissions and survival in adults with newly diagnosed acute lymphoblastic leukemia/lymphoma (ALL): Long-term follow-up of a prospective trial (ASH 2025) - P2 | "In a single-arm Phase II trial weconducted, DA-EPOCH ± rituximab (R) ± TKI yielded comparable morphologic (morph) and measurableresidual disease (MRD)- remissions with less toxicity than seen in a comparable cohort of patientsreceiving hyperCVAD. This study completed accrual in 2021, before routine upfront incorporation ofimmunotherapy and ponatinib (if Ph+)...Imatinib or dasatinib was added if Ph+, and R if CD20+...8 pts (15%) switched to blinatumomab whenMRD+ after DA-EPOCH, with none receiving it when MRD-. DA-EPOCH±R±TKI yields durable remissions, with survival comparable toimmunotherapy-based strategies for ALL... DA-EPOCH±R±TKI yields durable remissions, with survival comparable toimmunotherapy-based strategies for ALL. Unlike many other approaches, outcomes for older pts weresimilar to the general study population. These results support DA-EPOCH±R±TKI as a curative-intentoption, particularly in resource-limited settings."

Clinical • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • ABL1 • CD20

T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA RELAPSE AFTER CAR-T THERAPY (EBMT 2026) - "Background: Tisagenlecleucel (formerly CTL019), an anti-CD19 chimericantigen receptor (CAR) T-cell therapy, is an establishedtreatment for pediatric patients with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL)...Prior to CAR-T therapy, the patient received multiple chemotherapy regimens, including RE-ALL (with a measurable residual disease [MRD] of 38.36% at the end of induction phase 2), cytarabine and etoposide, hyper-CVAD, and blinatumomab (post-treatment bone marrow MRD of 59.7% blasts)...The patient underwent lymphodepletion with fludarabine (120 mg/m²) and cyclophosphamide (1000 mg/m²), followed by the first CAR-T cell infusion...The topotecan regimen was repeated, and a second CAR-T cell infusion was administered...A new treatment regimen with vincristine and PEG-asparaginase was initiated, followed by three doses of inotuzumab...Currently, six months after relapse, the patient remains on low-dose methotrexate and mercaptopurine, with..."

Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Inherited Retinal Dystrophy • Leukemia • Ophthalmology • T Acute Lymphoblastic Leukemia • T-cell Acute Lymphoblastic Lymphoma

AML16: A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov) - P2 | N=206 | Active, not recruiting | Sponsor: St. Jude Children's Research Hospital | Trial primary completion date: Jun 2025 ➔ Sep 2025

Trial primary completion date • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology

Systemic treatment of bone sarcoma, soft tissue sarcoma, GIST (PubMed, Rev Prat) - "Effective molecules are doxorubicin, alkyls, vinca-alkaloids and etoposide in Ewing's sarcomas, and methotrexate, doxorubicin, cisplatin, ifosfamide and etoposide in osteosarcoma. In high-risk gastro intestinal stromal tumor (GIST), the standard is 3 years adjuvant treatment with imatinib; a recent study asks whether treatment should continue for up to 6 years. In metastatic GIST, patients are treated with 4 successive lines of more or less specific tyrosine kinase inhibitors: imatinib, sunitinib, regorafenib, riprenib."

Journal • Review • Ewing Sarcoma • Oncology • Osteosarcoma • Sarcoma • Soft Tissue Sarcoma • Solid Tumor

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION POST–CAR-T THERAPY IN CHILDREN WITH PRE-B ACUTE LYMPHOBLASTIC LEUKAEMIA: NATIONAL POLISH EXPERIENCE (EBMT 2026) - "Conditioning regimens included total body irradiation with etoposide in nine patients; treosulfan, fludarabine, and thiotepa in two patients; and fludarabine with cyclophosphamide in one patient. Post-transplant complications included one patient developing severe veno-occlusive disease, treated with defibrotide. Four children developed acute skin graft-versus-hostdisease (GVHD): three responded to steroid therapy, while one had steroid-resistant GVHD requiring etanercept. One child experienced graft rejection and required a second HSCT.Two patients were treated with cidofovir for adenovirus reactivation, and one subsequently developed chronic bone marrow failure... Hematopoietic stem cell transplantation remains an important therapeutic strategy in selected patients following CAR-T therapy. The primary indication for HSCT in this setting isdisease relapse; however, second CAR-T infusions are increasingly considered. Allogeneic HSCT after CAR-T is also recommended as..."

Clinical • Acute Lymphocytic Leukemia • Aplastic Anemia • B Acute Lymphoblastic Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Hepatology • Immunology • Leukemia • Transplant Rejection • Transplantation • CD34

DeLLphi-312 Phase 3 Trial-in-Progress: Tarlatamab With Durvalumab, Carboplatin and Etoposide versus Durvalumab, Carboplatin and Etoposide As First-Line (1L) Therapy in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (ELCC 2026) - No abstract available

Clinical • P3 data • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Tarlatamab with a PD-L1 Inhibitor as First-Line Maintenance after Chemo-immunotherapy for ES-SCLC: DeLLphi-303 Phase 1b Study (IASLC-WCLC 2024) - P1, P3 | "Results : At data cutoff (31May2024), 88 patients (male: 62.5%, median age: 64.0 years; number of prior 1L platinum-etoposide cycles: 4, 86.4%; 5, 5.7%; 6, 8.0%) received tarlatamab with atezolizumab or durvalumab (Table). No new or unexpected toxicities were identified. This study supports further investigation of tarlatamab in combination with a PD-L1 inhibitor as 1LM in the ongoing phase 3 DeLLphi-305 randomized controlled study (NCT06211036)."

Clinical • P1 data • Anemia • Cardiovascular • Fatigue • Heart Failure • Hematological Disorders • Lung Cancer • Neutropenia • Oncology • Small Cell Lung Cancer • Solid Tumor • DLL3

Canadian Cancer Trials Group (CCTG) LY.17: A Randomized Phase II Study Evaluating Novel Salvage Therapy Pre-Autologous Stem Cell Transplant (ASCT) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR-DLBCL) - Outcome of Rituximab-Dose-Intensive Cyclophosphamide, Etoposide, Cisplatin (R-DICEP) Versus R-GDP (ASH 2022) - "Introduction: The CCTG LY.12 trial established rituximab combined with gemcitabine, dexamethasone and cisplatin (R-GDP) as a standard salvage chemotherapy option prior to ASCT for patients (pts) with relapsed/refractory (RR) DLBCL (Crump JCO 2014)...This report involves the component of the trial that randomly allocated pts to either 1 cycle of inpatient R-DICEP (Rituximab 375mg/m2 IV or 1400mg sc days 1 and 5 plus dose-intensive Cyclophosphamide 5.25g/m2, Etoposide 1050mg/m2, Cisplatin 105mg/m2 divided over days 2-4, with daily filgrastim starting day 15 until apheresis of blood stem cells approximately between days 20-22) or to 3 cycles of outpatient R-GDP... Although the 17% improvement in ORR for R-DICEP vs R-GDP in the second interim analysis exceeded the pre-specified 10% threshold required proceed to full accrual of 64 pts in the R-DICEP arm, we decided to stop accrual to the R-DICEP arm of the LY.17 trial due to slow accrual, higher AE rates, and greater..."

Clinical • P2 data • Atrial Fibrillation • Bone Marrow Transplantation • Cardiovascular • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Infectious Disease • Inflammation • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Pneumonia • Transplantation

Enhancing Recovery in Autologous Stem Cell Transplantation: The Impact of Filgrastim Prophylaxis in a Risk-Adapted Protocol (TCT-ASTCT-CIBMTR 2026) - "Initiating filgrastim on day +5 post-ASCT in high-risk patients significantly reduced LOS, neutrophil engraftment, and antibiotic usage, supporting this novel risk-adapted approach of use of filgrastim during ASCT. Figure 1: Cumulative event plot of time to neutrophil engraftment for matched participants (P = .003) Table 1: Baseline characteristics of matched participants. (The abbreviation RAP denotes risk adapted protocol, NF non filgrastim, Mdn median, IQR interquartile range, BEAM carmustine etoposide cytarabine melphalan, HDM high dose melphalan, RBuMelT rituximab busulfan melphalan thiotepa, ETOPMEL etoposide melphalan, and CyMelTBI cyclophosphamide melphalan total body irradiation.) Table 2: Secondary outcomes of matched participants (The abbreviation RAP denotes risk adapted protocol, NF non filgrastim, TNE time to neutrophil engraftment, Mdn median, IQR interquartile range, TPE time to platelet engraftment, DOT days of therapy, IV intravenous, and ABX..."

Clinical • Febrile Neutropenia • Hematological Malignancies • Infectious Disease • Lymphoma • Multiple Myeloma • Neutropenia • Transplantation